Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.

Multiplex Serology is a high-throughput technology developed to simultaneously measure specific serum antibodies against multiple pathogens in one reaction vessel. Serological assays for hepatitis B (HBV) and C (HCV) viruses, human T-lymphotropic virus 1 (HTLV-1) and the protozoan parasite Toxoplasm...

Full description

Bibliographic Details
Main Authors: Nicole Brenner, Alexander J Mentzer, Julia Butt, Kathrin L Braband, Angelika Michel, Katie Jeffery, Paul Klenerman, Barbara Gärtner, Paul Schnitzler, Adrian Hill, Graham Taylor, Maria A Demontis, Edward Guy, Stephen J Hadfield, Rachael Almond, Naomi Allen, Michael Pawlita, Tim Waterboer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0210407
id doaj-fce162ac7b7543709c293bcf121e8100
record_format Article
spelling doaj-fce162ac7b7543709c293bcf121e81002021-03-03T20:59:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01141e021040710.1371/journal.pone.0210407Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.Nicole BrennerAlexander J MentzerJulia ButtKathrin L BrabandAngelika MichelKatie JefferyPaul KlenermanBarbara GärtnerPaul SchnitzlerAdrian HillGraham TaylorMaria A DemontisEdward GuyStephen J HadfieldRachael AlmondNaomi AllenMichael PawlitaTim WaterboerMultiplex Serology is a high-throughput technology developed to simultaneously measure specific serum antibodies against multiple pathogens in one reaction vessel. Serological assays for hepatitis B (HBV) and C (HCV) viruses, human T-lymphotropic virus 1 (HTLV-1) and the protozoan parasite Toxoplasma gondii (T. gondii) were developed and validated against established reference assays. For each pathogen, between 3 and 5 specific antigens were recombinantly expressed as GST-tag fusion proteins in Escherichia coli and tested in Monoplex Serology, i.e. assays restricted to the antigens from one particular pathogen. For each of the four pathogen-specific Monoplex assays, overall seropositivity was defined using two pathogen-specific antigens. In the case of HBV Monoplex Serology, the detection of past natural HBV infection was validated based on two independent reference panels resulting in sensitivities of 92.3% and 93.0%, and specificities of 100% in both panels. Validation of HCV and HTLV-1 Monoplex Serology resulted in sensitivities of 98.0% and 95.0%, and specificities of 96.2% and 100.0%, respectively. The Monoplex Serology assay for T. gondii was validated with a sensitivity of 91.2% and specificity of 92.0%. The developed Monoplex Serology assays largely retained their characteristics when they were included in a multiplex panel (i.e. Multiplex Serology), containing additional antigens from a broad range of other pathogens. Thus HBV, HCV, HTLV-1 and T. gondii Monoplex Serology assays can efficiently be incorporated into Multiplex Serology panels tailored for application in seroepidemiological studies.https://doi.org/10.1371/journal.pone.0210407
collection DOAJ
language English
format Article
sources DOAJ
author Nicole Brenner
Alexander J Mentzer
Julia Butt
Kathrin L Braband
Angelika Michel
Katie Jeffery
Paul Klenerman
Barbara Gärtner
Paul Schnitzler
Adrian Hill
Graham Taylor
Maria A Demontis
Edward Guy
Stephen J Hadfield
Rachael Almond
Naomi Allen
Michael Pawlita
Tim Waterboer
spellingShingle Nicole Brenner
Alexander J Mentzer
Julia Butt
Kathrin L Braband
Angelika Michel
Katie Jeffery
Paul Klenerman
Barbara Gärtner
Paul Schnitzler
Adrian Hill
Graham Taylor
Maria A Demontis
Edward Guy
Stephen J Hadfield
Rachael Almond
Naomi Allen
Michael Pawlita
Tim Waterboer
Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
PLoS ONE
author_facet Nicole Brenner
Alexander J Mentzer
Julia Butt
Kathrin L Braband
Angelika Michel
Katie Jeffery
Paul Klenerman
Barbara Gärtner
Paul Schnitzler
Adrian Hill
Graham Taylor
Maria A Demontis
Edward Guy
Stephen J Hadfield
Rachael Almond
Naomi Allen
Michael Pawlita
Tim Waterboer
author_sort Nicole Brenner
title Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
title_short Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
title_full Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
title_fullStr Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
title_full_unstemmed Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
title_sort validation of multiplex serology for human hepatitis viruses b and c, human t-lymphotropic virus 1 and toxoplasma gondii.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description Multiplex Serology is a high-throughput technology developed to simultaneously measure specific serum antibodies against multiple pathogens in one reaction vessel. Serological assays for hepatitis B (HBV) and C (HCV) viruses, human T-lymphotropic virus 1 (HTLV-1) and the protozoan parasite Toxoplasma gondii (T. gondii) were developed and validated against established reference assays. For each pathogen, between 3 and 5 specific antigens were recombinantly expressed as GST-tag fusion proteins in Escherichia coli and tested in Monoplex Serology, i.e. assays restricted to the antigens from one particular pathogen. For each of the four pathogen-specific Monoplex assays, overall seropositivity was defined using two pathogen-specific antigens. In the case of HBV Monoplex Serology, the detection of past natural HBV infection was validated based on two independent reference panels resulting in sensitivities of 92.3% and 93.0%, and specificities of 100% in both panels. Validation of HCV and HTLV-1 Monoplex Serology resulted in sensitivities of 98.0% and 95.0%, and specificities of 96.2% and 100.0%, respectively. The Monoplex Serology assay for T. gondii was validated with a sensitivity of 91.2% and specificity of 92.0%. The developed Monoplex Serology assays largely retained their characteristics when they were included in a multiplex panel (i.e. Multiplex Serology), containing additional antigens from a broad range of other pathogens. Thus HBV, HCV, HTLV-1 and T. gondii Monoplex Serology assays can efficiently be incorporated into Multiplex Serology panels tailored for application in seroepidemiological studies.
url https://doi.org/10.1371/journal.pone.0210407
work_keys_str_mv AT nicolebrenner validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT alexanderjmentzer validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT juliabutt validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT kathrinlbraband validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT angelikamichel validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT katiejeffery validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT paulklenerman validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT barbaragartner validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT paulschnitzler validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT adrianhill validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT grahamtaylor validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT mariaademontis validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT edwardguy validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT stephenjhadfield validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT rachaelalmond validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT naomiallen validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT michaelpawlita validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
AT timwaterboer validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii
_version_ 1714819472894722048